首页 | 本学科首页   官方微博 | 高级检索  
检索        

消瘰丸治疗淋巴瘤基于PD-1/PD-L1信号通路的机制研究
引用本文:刘群英,张博,李海燕,董雷,孙超逸,杨明珠,孙凇,倪磊.消瘰丸治疗淋巴瘤基于PD-1/PD-L1信号通路的机制研究[J].天津中医药,2018,35(5):370-375.
作者姓名:刘群英  张博  李海燕  董雷  孙超逸  杨明珠  孙凇  倪磊
作者单位:北京中医药大学中医学院;天津国际生物医药联合研究院;北京中医药大学东直门医院;北京中医药大学东方医院
基金项目:北京中医药大学基本科研业务费自主选题项目(在读研究生项目,2017-JYB-XS011)。
摘    要:目的]初步探究古方消瘰丸治疗淋巴瘤基于程序性死亡因子(PD-1)/程序性死亡因子配体1(PD-L)信号通路上的免疫调控机制。方法]从健康人、淋巴瘤患者的外周血中分离外周血单个核细胞,体外培养刺激后,应用流式细胞仪、CFSE等技术,以PD-1/PD-L1信号通路为靶通路,通过是否阻断PD-1/PD-L1信号通路与消瘰丸药物干预,观察消瘰丸对T细胞不同亚细胞的活性作用。结果]淋巴瘤患者T淋巴瘤细胞在消瘰丸干预下,CD4~+T细胞PD-1(+)和CD69表达降低,而CD8~+T细胞PD-1(+)和CD69表达增加;PD-L1阻断剂和消瘰丸联合使用对淋巴瘤T细胞中的CD4~+细胞CD69抑制作用比PD-L1阻断剂组和消瘰丸组都明显;与PD-L1阻断剂组相比,消瘰丸组CD8~+T细胞活性增加更明显,而同时加入两者,与消瘰丸组相比,增加并不明显。结论]消瘰丸对大量异常增殖的CD4~+T细胞可以抑制PD-1(+)的高表达,消瘰丸与PD-L1阻断剂二者对于CD4~+PD-1(+)和CD69表达有协同降低的作用;消瘰丸对于有细胞毒作用的CD8~+T细胞活性有增强作用,可以促进PD-1(+)的表达。

关 键 词:消瘰丸  淋巴瘤  PD-1/PD-L1信号通路
收稿时间:2017/12/16 0:00:00

Mechanism research on the treatment of lymphoma with Xiaoluo pill based on PD-1/PD-L1 signaling pathway
LIU Qunying,ZHANG Bo,LI Haiyan,DONG Lei,SUN Chaoyi,YANG Mingzhu,SUN Song and NI Lei.Mechanism research on the treatment of lymphoma with Xiaoluo pill based on PD-1/PD-L1 signaling pathway[J].Tianjin Journal of Traditional Chin Medicine,2018,35(5):370-375.
Authors:LIU Qunying  ZHANG Bo  LI Haiyan  DONG Lei  SUN Chaoyi  YANG Mingzhu  SUN Song and NI Lei
Institution:Beijing University of Chinese Medicine, Beijing 100029, China,Tianjin International Joint Academy of Biomedicine, Tianjin 300457, China,Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine, Beijin 100700, China,Dongfang Hospital of Beijing University of Traditional Chinese Medicine, Beijin 100078, China,Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine, Beijin 100700, China,Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine, Beijin 100700, China,Dongfang Hospital of Beijing University of Traditional Chinese Medicine, Beijin 100078, China and Beijing University of Chinese Medicine, Beijing 100029, China
Abstract:Objective] To investigate the immunoregulatory mechanism based on PD-1/PD-L1 signaling pathway in the treatment of Lymphoma with Xiaoluo pill.Methods] Peripheral blood mononuclear cells (PBMC) were isolated from the peripheral blood of healthy people and lymphoma patients. After the cells were cultured in vitro, the activity of different subcellular cells of T cells was observed by whether to block the PD-1/PD-L1 signal pathway and drug intervention, which was detected by flow cytometry, CFSE and other technologies based on PD-1/PD-L1 signal target pathway.Results] The expressions of PD-1 (+) and CD69 were decreased in CD4+ T cells and increased in CD8+ T cells in patients with T lymphoma. The inhibitory effect on CD69 in CD4+ cells in lymphoma T cells in combination therapy of PD-L1 blockade and Xiaoluo pill was significantly higher than that in PD-L1 blockade group and Xiaoluo pill group alone. Compared with the PD-L1 blockade group, the activity of CD8+ T cells increased significantly in Xiaoluo pill group. And compared with Xiaoluo pill group, the activity of CD8+ T cells in combination therapy of PD-L1 blockade and Xiaoluo pill was not significantly increased.Conclusion] Xiaoluo pill could inhibit the high expression of PD-1 (+) on a large number of aberrant proliferative CD4+ T cells; both Xiaoluo pill and PD-L1 blockade have a synergistic effect on PD-1 (+) and CD69 expression in CD4+ T cells; Xiaoluo pill has a potent effect on CD8+ T cell activity and could promote PD-1 (+) expression.
Keywords:Xiaoluo pill  lymphoma  PD-1/PD-L1 signal pathway
本文献已被 CNKI 等数据库收录!
点击此处可从《天津中医药》浏览原始摘要信息
点击此处可从《天津中医药》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号